Identifying Novel Biomarkers Associated with Bladder Cancer Treatment Outcomes

Overview

Journal Front Oncol

Specialty Oncology

Date 2023 Apr 17

PMID 37064102

Authors

Peris R Castaneda

Dan Theodorescu

Charles J Rosser

Michael Ahdoot

Affiliations

Soon will be listed here.

Abstract

Bladder cancer is a complex disease with variable prognosis. Recent investigations into the molecular landscape of bladder cancer have revealed frequent genetic alterations and molecular subtypes with therapeutic implications. Consequently, a shift toward personalized treatment of bladder cancer is underway. To this end, several biomarkers have been developed and tested in their ability to predict response to treatment in patients with bladder cancer and potentially help direct therapy. We performed a search of recently published PubMed articles using terms "biomarker," "bladder cancer," and the respective treatment discussed (i.e., "neoadjuvant" or "BCG"). In this review, we summarize the latest studies on novel biomarkers in bladder cancer with a focus on those intended to improve risk stratification and treatment selection.

Citing Articles

An unfolded protein response (UPR)-signature regulated by the NFKB-miR-29b/c axis fosters tumor aggressiveness and poor survival in bladder cancer.

Zhang J, Fan X, Chen Y, Han Y, Yu W, Zhang S Front Mol Biosci. 2025; 12:1542650.

PMID: 40026699 PMC: 11867963. DOI: 10.3389/fmolb.2025.1542650.

Elevated expression of gene in tumors is a poor prognostic biomarker for patients with bladder cancer.

Franco L, Arunachalam S, Chauhan A, Kareff S, Hallenbeck P Front Mol Biosci. 2025; 11:1520223.

PMID: 39917181 PMC: 11798775. DOI: 10.3389/fmolb.2024.1520223.

AI predicting recurrence in non-muscle-invasive bladder cancer: systematic review with study strengths and weaknesses.

Abbas S, Shafik R, Soomro N, Heer R, Adhikari K Front Oncol. 2025; 14():1509362.

PMID: 39839785 PMC: 11746116. DOI: 10.3389/fonc.2024.1509362.

Bladder cancer biomarkers: current approaches and future directions.

Ahangar M, Mahjoubi F, Mowla S Front Oncol. 2024; 14:1453278.

PMID: 39678505 PMC: 11638051. DOI: 10.3389/fonc.2024.1453278.

Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization.

Hori K, Yamada S, Murata K, Miyata H, Mizue Y, Murai A Hum Vaccin Immunother. 2024; 20(1):2414542.

PMID: 39539024 PMC: 11572277. DOI: 10.1080/21645515.2024.2414542.

References

Chamie K, Litwin M, Bassett J, Daskivich T, Lai J, Hanley J . Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013; 119(17):3219-27. PMC: 3773281. DOI: 10.1002/cncr.28147. View

Hernandez S, Lopez-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, Amoros A . FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res. 2005; 11(15):5444-50. DOI: 10.1158/1078-0432.CCR-05-0122. View

Hedegaard J, Lamy P, Nordentoft I, Algaba F, Hoyer S, Ulhoi B . Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. Cancer Cell. 2016; 30(1):27-42. DOI: 10.1016/j.ccell.2016.05.004. View

Necchi A, Anichini A, Raggi D, Briganti A, Massa S, Luciano R . Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. J Clin Oncol. 2018; 36(34):3353-3360. DOI: 10.1200/JCO.18.01148. View

Groenendijk F, De Jong J, Fransen van de Putte E, Michaut M, Schlicker A, Peters D . ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy. Eur Urol. 2015; 69(3):384-8. DOI: 10.1016/j.eururo.2015.01.014. View

Dancik G, Theodorescu D . Using Cell Lines To Guide Neoadjuvant Therapy in Bladder Cancer: COXEN and SWOG S1314. Eur Urol Focus. 2022; 8(3):648-650. PMC: 10112179. DOI: 10.1016/j.euf.2022.03.013. View

Zhao J, Xu W, Zhang Z, Song R, Zeng S, Sun Y . Prognostic role of HER2 expression in bladder cancer: a systematic review and meta-analysis. Int Urol Nephrol. 2014; 47(1):87-94. DOI: 10.1007/s11255-014-0866-z. View

Smith A, Deal A, Woods M, Wallen E, Pruthi R, Chen R . Muscle-invasive bladder cancer: evaluating treatment and survival in the National Cancer Data Base. BJU Int. 2013; 114(5):719-26. DOI: 10.1111/bju.12601. View

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

10.

Zhang Y, Lv Y, Niu Y, Su H, Feng A . Role of Circulating Tumor Cell (CTC) Monitoring in Evaluating Prognosis of Triple-Negative Breast Cancer Patients in China. Med Sci Monit. 2017; 23:3071-3079. PMC: 5493060. DOI: 10.12659/msm.902637. View

11.

Lotan Y, de Jong J, Liu V, Bismar T, Boorjian S, Huang H . Patients with Muscle-Invasive Bladder Cancer with Nonluminal Subtype Derive Greatest Benefit from Platinum Based Neoadjuvant Chemotherapy. J Urol. 2021; 207(3):541-550. DOI: 10.1097/JU.0000000000002261. View

12.

Liang L, Kong M, Zhou S, Sheng Y, Wang P, Yu T . An integrated double-filtration microfluidic device for isolation, enrichment and quantification of urinary extracellular vesicles for detection of bladder cancer. Sci Rep. 2017; 7:46224. PMC: 5402302. DOI: 10.1038/srep46224. View

13.

Mouw K . DNA Repair Pathway Alterations in Bladder Cancer. Cancers (Basel). 2017; 9(4). PMC: 5406703. DOI: 10.3390/cancers9040028. View

14.

Wan J . Survival Outcomes of Early versus Deferred Cystectomy for High-Grade Non-Muscle-Invasive Bladder Cancer: A Systematic Review. Curr Urol. 2020; 14(2):66-73. PMC: 7390979. DOI: 10.1159/000499257. View

15.

Siegel R, Miller K, Fuchs H, Jemal A . Cancer statistics, 2022. CA Cancer J Clin. 2022; 72(1):7-33. DOI: 10.3322/caac.21708. View

16.

Jutte H, Reike M, Wirtz R, Kriegmair M, Erben P, Tully K . KRT20, KRT5, ESR1 and ERBB2 Expression Can Predict Pathologic Outcome in Patients Undergoing Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Bladder Cancer. J Pers Med. 2021; 11(6). PMC: 8229873. DOI: 10.3390/jpm11060473. View

17.

Powles T, Kockx M, Rodriguez-Vida A, Duran I, Crabb S, van der Heijden M . Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med. 2019; 25(11):1706-1714. DOI: 10.1038/s41591-019-0628-7. View

18.

Duplisea J, Mason R, Reichard C, Li R, Shen Y, Boorjian S . Trends and disparities in the use of neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma. Can Urol Assoc J. 2018; 13(2):24-28. PMC: 6363565. DOI: 10.5489/cuaj.5405. View

19.

Rodriguez-Vida A, Lerner S, Bellmunt J . The Cancer Genome Atlas Project in Bladder Cancer. Cancer Treat Res. 2018; 175:259-271. DOI: 10.1007/978-3-319-93339-9_12. View

20.

Chang S, Boorjian S, Chou R, Clark P, Daneshmand S, Konety B . Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline. J Urol. 2016; 196(4):1021-9. DOI: 10.1016/j.juro.2016.06.049. View